IP Library Granted Patent US 8,992,909
Granted Patent B2
US 8,992,909 · App. 13/402,698 · Granted Mar 31, 2015

Methods of increasing bone mass in a subject comprising inhibiting DKK1

Inventors: John D Shaughnessy, Jr. (Roland, AR); Bart Barlogie (Little Rock, AR); Ya-Wei Qiang (Little Rock, AR)
Assignee: Board of Trustees of the University of Arkansas
C07K16/18C07K16/30C12Q1/6886G01N33/6893A61K2039/505C07K2316/96C12Q2600/136G01N2333/4703G01N2800/108
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,992,909
App. No.
13/402,698
Granted
Mar 31, 2015
Kind
B2
Abstract

The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.

Claims (6)

1. A method of increasing osteoblast activity in a subject exhibiting increased DKK1 activity or expression, comprising the step of:

administering to the subject an agent that is a DKK1 neutralizing antibody that binds a DKK1 protein consisting of the sequence encoded by the DKK1 gene consisting of the sequence shown in SEQ ID No: 47, wherein the agent inhibits the activity of the DKK1 protein.

2. A method of inhibiting osteoclast activity in a subject, exhibiting increased DKK1 activity or expression, comprising the step of:

administering to the subject an agent that is a DKK1 neutralizing antibody that binds a DKK1 protein consisting of the sequence encoded by the DKK1 gene consisting of the sequence shown in SEQ ID No: 47, wherein the agent inhibits the activity of the DKK1 protein.

3. A method of increasing bone mass in a subject, exhibiting increased DKK1 activity or expression, comprising the step of:

administering to the subject an agent that is a DKK1 neutralizing antibody that binds a DKK1 protein consisting of the sequence encoded by the DKK1 gene consisting of the sequence shown in SEQ ID No: 47, wherein the agent inhibits the activity of the DKK1 protein.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 23, 2012
From: UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028833/0739 →
Continuity (6)
Continuation 12008771 · Jan 14, 2008
Continuation In Part 11588008 · Oct 26, 2006
Continuation In Part 11176739 · Jul 7, 2005
Continuation In Part 10727461 · Dec 4, 2003
Provisional Application 60431040 · Dec 5, 2002
Related Publication 20130052199A1 · Feb 28, 2013